Table 2.
Estimated marginal means for different groups and treatment type
| Type × time | Mean difference (T24−T48)a | P | Mean difference (T48−T72)a | P |
|---|---|---|---|---|
| Promastigote | 2.09 (28.50−26.41) | 0.012 | 2.65 (26.41−23.67) | 0.001 |
| Amastigote | 11.19 (63.30−52.11) | 11.92 (52.11−40.19) | ||
| Group × time | Mean difference (T24−T48) | P | Mean difference (T48−T72)a | P |
| NC (Negative Control) | 0 (100.00−100.00) | 0.031 | 0 (100.00−100.00) | 0.047 |
| Amphotericin B | 10.88 (25.55−14.67) | 6.65 (14.67−8.02) | ||
| Imatinib 25 | 8.9 (43.65−34.75) | 12.28 (34.75−22.47) | ||
| Imatinib 50 | 6.84 (33.57−26.73) | 9.2 (26.73−22.47) | ||
| Imatinib 100 | 6.6 (26.73−20.13) | 8.26 (20.13−11.87) | ||
| Group × type × time | Mean difference (T24−T48) | P | Mean difference (T48−T72)a | P |
| Promastigote and NC | 0 (100.00−100.00) | 0.112 | 0 (100.00−100.00) | 0.011 |
| Amastigote and NC | 0 (100.00−100.00) | 0 (100.00−100.00) | ||
| Promastigote and amphotericin B | 0.33 (1.13−0.80) | 0.17 (0.80−0.63) | ||
| Amastigote and amphotericin B | 21.44 (49.97−28.53) | 13.13 (28.63−15.40) | ||
| Promastigote and imatinib 25 | 4.7 (20.67−15.97) | 6.67 (15.97−9.30) | ||
| Amastigote and imatinib 25 | 13.1 (66.63−53.53) | 17.9 (53.53−35.63) | ||
| Promastigote and imatinib 50 | 3.16 (13.83−10.67) | 4.14 (10.67−10.53) | ||
| Amastigote and imatinib 50 | 10.5 (53.30−42.80) | 14.27 (42.80−28.53) | ||
| Promastigote and imatinib 100 | 2.27 (6.87−44.60) | 2.27 (4.60−2.33) | ||
| Amastigote and imatinib 100 | 10.93 (46.60−35.67) | 14.27 (35.67−21.40) | ||
aThe mean difference is significant at the 0.05 level